Advances in apheresis technology have made single donor platelets easi
er to obtain and therefore more plentiful. There are some hypothesized
advantages to single donor platelets including reduced disease transm
ission, reduced alloimmunization, and superior function and storage ch
aracteristics, These ideas have swayed some to insist that single dono
r platelets should become the routine platelet transfusion component.
While support exists for some of these benefits, there is no consensus
that the risks to donors, the difficulties of setting up a program, a
nd the expenses are sufficiently outweighed that the conversion of blo
od banks to a single donor platelet supply is merited. The major advan
tage to single donor platelets is that the selection of certain donor
characteristics, such as HLA compatibility, is facilitated since a tot
al dose of platelets is coming from one donor.